Compelling Benefit of Soluble Suppression of Tumorigenicity‐2 in Post–Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic

I t is estimated that in the United States, each year, >780 000 people will experience an acute coronary syndrome.Approximately 70% of these people will have a non-ST-elevated myocardial infarction (NSTEMI), and the rest will have an ST-elevated myocardial infarction (STEMI). 1 Patients with NSTEMI typically have more comorbidities, both cardiac and noncardiac, than patients with STEMI.In both STEMI and NSTEMI, risk estimation by current guidelines recommends the use of the TIMI (Thrombolysis in Myocardial Infarction) or GRACE (Global Registry of Acute Cardiac Events) risk scores.The TIMI risk score is composed of 7, 1-point risk indicators (≥65 years of age, ≥3 risk factors for coronary artery disease, prior coronary stenosis ≥50%, ST deviation on ECG, ≥2 anginal events in prior 24 hours, use of aspirin in prior 7 days, and elevated cardiac enzyme levels), 2 and it has been validated internally within the TIMI 11B trial and in 2 separate cohorts of patients from the ESSENCE (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events) trial, 3 published 20 years ago.The TIMI risk score calculator is available at http://www.timi.org.The GRACE risk model predicts in-hospital and postdischarge mortality of MI. 4,5 The GRACE tool was developed from 11 389 patients in GRACE and validated in subsequent